Back
GLOPID-R - CEPI's 3.5bn Plan
webTangentially relevant to AI safety as a case study in international coordination and governance for catastrophic biological risks; CEPI's model of multi-stakeholder coordination may offer lessons for AI governance efforts addressing global catastrophic risks.
Metadata
Importance: 22/100news articlenews
Summary
This article outlines CEPI's (Coalition for Epidemic Preparedness Innovations) ambitious $3.5 billion fundraising and strategic plan aimed at accelerating vaccine development to combat current and future epidemic and pandemic threats. The plan focuses on compressing vaccine development timelines and building global preparedness infrastructure. It represents a major international coordination effort in biological risk reduction.
Key Points
- •CEPI aims to raise $3.5 billion to fund rapid vaccine development against epidemic and pandemic pathogens
- •The strategy targets compressing vaccine development timelines to 100 days for future outbreak response
- •Focuses on building global manufacturing and distribution infrastructure for equitable vaccine access
- •Addresses both known epidemic threats and unknown 'Disease X' pathogens through platform technologies
- •Represents coordinated international governance effort spanning public, private, and philanthropic sectors
Cited by 1 page
| Page | Type | Quality |
|---|---|---|
| Coalition for Epidemic Preparedness Innovations | Organization | 53.0 |
Cached Content Preview
HTTP 200Fetched Mar 20, 20266 KB
[](https://www.glopid-r.org/)
# CEPI’s $3.5bn plan to tackle the outbreaks of today and tomorrow
The Coalition for Epidemic Preparedness Innovations (CEPI), an observer member of GloPID-R, has played a key role in efforts to develop and deploy COVID-19 vaccines. It’s also planning for future threats.
The global COVID-19 vaccine development and deployment effort has been truly remarkable. Over 1.8 billion shots have been administered worldwide, including nearly 78 million doses through COVAX, our global initiative with Gavi, the World Health Organization (WHO), and delivery partner UNICEF, to enable doses to reach vulnerable populations in all countries.
CEPI has been central to these efforts, rapidly building one of the world’s largest COVID-19 vaccine portfolios, supporting enabling sciences and vaccine manufacturing work, and including access requirements into our agreements with vaccine developers to secure supply of doses to COVAX.
While we continue to urgently push for greater vaccine equity and respond to the emergence of novel variants, this is not the only current focus for CEPI. Knowing that the next pandemic is not a case of if, but when means that we are also using this unique, historic, and rare alignment of lived experience, recognition of scientific power, and political will to advance global pandemic preparedness.
In March 2021, CEPI launched its forward-looking [$3.5bn plan](https://cepi.net/news_cepi/cepi-launches-plan-to-tackle-risk-of-future-pandemics-and-epidemics/) which seeks to reduce or even mitigate the risk of future epidemic and pandemic threats. Under the strategic pillars of prepare, transform and connect, the five-year strategy includes several ambitious programmes which aim to build upon the lessons of COVID-19 to create a suite of new, life-saving tools to fight the next big outbreak.
One area of focus for CEPI seeks to reduce the vaccine development timeline to a 100-day target. Faster research, production, and deployment would not only have saved many of the 3.3 million lives lost so far to COVID-19, it would also have prevented trillions of dollars of economic damage and limited or possibly have prevented the emergence of novel variants which could impact vaccine performance.
Global scientific collaboration, substantial funding, and ongoing political support will be critical to achieving this 100-day ambition. This will allow for significant investments to be made in pioneering technologies and innovative trial designs which can shorten the research and clinical evaluation process.
In its quest to meet the speedy goal, CEPI will also be developing a library of vaccines to work against whole virus families, as an alternative to current methods aiming to deve
... (truncated, 6 KB total)Resource ID:
e7ca9fb78859f68f | Stable ID: NDdmMmUwNz